Zuclopenthixol Ong-Acting Im Injection (Depot) Suppliers & Bulk Manufacturers
Available Forms: Long-acting IM Injection (Depot)
Available Strengths: 200 mg/mL, 500 mg/mL
Reference Brands: Clopixol Depot®(US)
Category:
Antipsychotropic Drugs
Zuclopenthixol is a typical antipsychotic that works by blocking dopamine (D2) receptors in the brain, reducing psychotic symptoms. It’s primarily used as a long-acting intramuscular injection to manage schizophrenia, particularly in patients with poor medication compliance. It helps maintain symptom control over extended periods.
Zuclopenthixol ong-acting IM Injection (Depot) is available in Long-acting IM Injection (Depot)
and strengths such as 200 mg/mL, 500 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Zuclopenthixol ong-acting IM Injection (Depot) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Zuclopenthixol ong-acting IM Injection (Depot) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Zuclopenthixol long-acting IM injection, a typical antipsychotic depot formulation, is not FDA-approved in the United States but is widely authorized in the EU under the brand Clopixol Depot. In Europe, it follows EMA guidelines for long-acting injectable neuroleptics, indicated for schizophrenia and related psychoses. EU compliance requires GMP manufacturing, stability data, and pharmacovigilance alignment. U.S. market entry may involve a 505(b)(2) pathway and complete ANDA dossier. To explore dossier-ready forms, formulations, and global suppliers of Zuclopenthixol long-acting IM injection, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing